RET in Lung Cancer: The Next Big Target? episode artwork

EPISODE · Jul 7, 2015 · 3 MIN

RET in Lung Cancer: The Next Big Target?

from GRACEcast · host cancerGRACE Meetings

A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.

Episode metadata supplied by the publisher feed · Published Jul 7, 2015

Embed this episode

NOW PLAYING

RET in Lung Cancer: The Next Big Target?

0:00 3:32

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 3 minutes long.

When was this GRACEcast episode published?

This episode was published on July 7, 2015.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!